Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists and the Eurasian Association of Cardio-Oncologists. “Cardioprotection 2025: Modern Approaches to Preventing Cardiotoxicity in Antitumor Therapy”. Part I. Introduction, Objectives, Cardiotoxicity Detection Methods and Risk Stratification

The purpose of this document is to provide updated, evidence-based recommendations for the prevention of cardiovascular toxicity associated with anticancer therapy (anthracyclines, HER2-targeted therapy, tyrosine kinase inhibitors, anti-VEGF agents, fluoropyrimidines, and immune checkpoint inhibitors). The consensus covers risk stratification, screening and monitoring (biomarkers and imaging), pharmacological and non-pharmacological cardioprotection, and patient management algorithms for the detection of subclinical and clinically significant damage to the cardiovascular system. The recommendations are structured by recommendation classes (I, IIa, IIb, III) and levels of evidence (A, B, C), and are adapted for Russian and Eurasian clinical practice.

1. Kaprin A.D., Matskeplishvili S.T., Potievskaya V.I., Popovkina O.E., Bolotina L.V., Shklyaeva A.V. et al. Cardiovascular diseases in cancer patients. P.A. Herzen Journal of Oncology. 2019;8(2):139–47. DOI: 10.17116/onkolog20198021139

2. Dauccia C, Agostinetto E, Arecco L, Lobo-Martins S, Gitto M, Lyon AR et al. Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care. ESMO Open. 2025;10(6):105128. DOI: 10.1016/j.esmoop.2025.105128

3. Vasyuk Yu.A., Roitberg G.E., Belenkov Yu.N., Ointoktinova O.Sh., Gendlin G.E., Matskeplishvili S.T. et al. Interdisciplinary consensus of the Expert Council. Cardiovascular toxicity in cancer patients due to chemo- and radiation therapy in modern clinical practice (part 2). Professor’s Journal. Series: Medical Sciences. 2024;3–4:25–51. DOI: 10.18572/2658-7130-2024-3-4-25-51

4. Vasyuk Yu.A., Shupenina E.Yu., Vyzhigin D.A., Novosel E.O. Cardiooncology. A guide for doctors. - M.: GEOTAR-Media; 2025. - 304p. ISBN 978-5-9704-9003-7

5. Kaprin A.D., Potievskaya V.I., Abuzarova G.R., Ageev F.T., Alkidzhonov F.R., Alekseeva G.S. et al. Cardiology Guidelines. - M.: GEOS Publishing House LLC; 2024. - 616p. ISBN 978-5-89118-887-7

6. Kirichenko Yu.Yu., Ilgisonis I.S., Ivanova T.V., Zolotukhina A.S., Khabarova N.V., Privalova E.V. et al. Cardiovascular toxicity of antitumor therapy: effect on myocardial and vascular remodeling. Cardiovascular Therapy and Prevention. 2021;20(7):58–66. DOI: 10.15829/1728-8800-2021-2923

7. Blaes A, Nohria A, Armenian S, Bergom C, Thavendiranathan P, Barac A et al. Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations. JACC: CardioOncology. 2025;7(1):1–19. DOI: 10.1016/j.jaccao.2024.06.006

8. Murtuzaliev Sh.M., Salakheeva E.Yu., Kardovskaya S.A., Kirichenko Yu.Yu., Siderko E.A., Belenkov Yu.N. et al. Cardiovascular toxicity of CAR-T cell therapy: a literature review. Clinical Oncohematology. 2024;17(4):404–14. DOI: 10.21320/2500-2139-2024-17-4-404-414

9. Vitsenya M.V., Ageev F.T., Gilyarov M.Yu., Ovchinnikov A.G., Orlova R.V., Poltavskaya M.G. Practical recommendations for the correction of cardiovascular toxicity of anticancer drug therapy. Malignant tumours. 2021;11(3s2-2):78–98. DOI: 10.18027/2224-5057-2021-11-3s2-41

10. Ghigo A, Ameri P, Asnani A, Bertero E, De Boer RA, Farmakis D et al. Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart. European Journal of Heart Failure. 2025;27(6):1028–46. DOI: 10.1002/ejhf.3636

11. Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A et al. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure. 2025;31(2):415–55. DOI: 10.1016/j.cardfail.2024.08.045

12. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244

13. Belenkov Yu.N., Ilgisonis I.S., Kirichenko Yu.Yu., Murtuzaliev Sh.M. Cardio-oncology today: digest of the first European clinical guidelines (2022). Kardiologiia. 2023;63(7):3–15. DOI: 10.18087/cardio.2023.7.n2445

14. Čelutkienė J, Pudil R, López‐Fernández T, Grapsa J, Nihoyannopoulos P, Bergler‐Klein J et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European Journal of Heart Failure. 2020;22(9):1504–24. DOI: 10.1002/ejhf.1957

15. Zhang M, Li D-F, Pu J. Chinese guideline for the clinical application of noninvasive imaging technology in accessing cancer therapy-related cardiovascular toxicity. Journal of Geriatric Cardiology. 2025;22(5):477–96. DOI: 10.26599/1671-5411.2025.05.006

16. Khabarova N.V., Kirichenko Yu.Yu., Belenkov Yu.N., Tarlovskaya E.I., Shestakova K.M., Vasyuk Yu.A. Multiparametric Integrative Model for Predicting the Risk of Developing Cardiovascular Vasculotoxicity in Antitumor Therapy: Prospects for Personalized Stratification of Cancer Patients. Kardiologiia. 2025;65(9):19–25. DOI: 10.18087/cardio.2025.9.n3017

17. Lyon AR, Dent S, Stanway S, Earl H, Brezden‐Masley C, Cohen‐Solal A et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure. 2020;22(11):1945–60. DOI: 10.1002/ejhf.1920

18. Belenkov Yu.N., Ilgisonis I.S., Khabarova N.V., Kirichenko Yu.Yu. Modern Instrumental Methods of Diagnostics and Risk Assessment of Developing Antitumor Therapy Cardiovasculotoxicity. Kardiologiia. 2024;64(8):3–12. DOI: 10.18087/cardio.2024.8.n2753

19. Ghose A, Kandala A, Sabnis I, Hasanova M, Simela C, Manisty C et al. A call to action: improving access to cardiac MRI for diagnosis of immune checkpoint inhibitor related myocarditis in low and middle income countries. Cardio-Oncology. 2025;11(1):97. DOI: 10.1186/s40959-025-00393-8

20. Khabarova N.V., Ilgisonis I.S., Kirichenko Yu.Yu., Gagarina N.V., Belenkov Yu.N. Multispiral computed tomography as a promising method for detecting cardiovascular toxicity of antitumor therapy. Creative Cardiology. 2024;18(S):139–47. DOI: 10.24022/1997-3187-2024-18S-S139-S147

21. Cardiovascular Expert Committee of Chinese Medical Doctor Association of Laboratory Medicine, Section of Cardio-Oncology Group of Chinese Society of Cardiology. Chinese expert consensus on cardiac biomarkers for monitoring and management of cardiovascular toxicity in cancer therapy (2024 edition). Zhonghua Yi Xue Za Zhi. 2024;104(36):3371–85. DOI: 10.3760/cma.j.cn112137-20240510-01091

22. Jovenaux L, Cautela J, Resseguier N, Pibarot M, Taouqi M, Orabona M et al. Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey. International Journal of Cardiology. 2017;241:387–92. DOI: 10.1016/j.ijcard.2017.02.154

23. Mao H, Hu J, Yu C, Xie S, Chang C, Peng J et al. MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances. Frontiers in Cardiovascular Medicine. 2025;12:1614878. DOI: 10.3389/fcvm.2025.1614878

24. Vitsenya M.V., Potekhina A.V., Gavryushina S.V., Ibragimova N.M., Guchaev R.V., Stenina M.B. et al. Effectiveness of risk-guided cardiac management in patients with HER2-positive breast cancer and cancer therapy-related cardiac dysfunction. Russian Cardiology Bulletin. 2024;19(4–2):144–53. DOI: 10.17116/Cardiobulletin202419042144

25. Haj-Yehia E, Michel L, Mincu RI, Rassaf T, Totzeck M. Prevention of cancer-therapy related cardiac dysfunction. Current Heart Failure Reports. 2025;22(1):9. DOI: 10.1007/s11897-025-00697-x

26. Keramida K, Lopez‐Fernandez T, Anker MS, Petrie MC, Ameri P, Anderson LJ et al. Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology. European Journal of Heart Failure. 2025;ejhf.70005. [Epub ahead of print]. DOI: 10.1002/ejhf.70005

27. Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(5):655–77. DOI: 10.1016/j.jaccao.2024.07.016

28. Minotti G, Reggiardo G, Camilli M, Salvatorelli E, Menna P. From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: a translational approach. JACC: CardioOncology. 2022;4(1):139–40. DOI: 10.1016/j.jaccao.2021.12.002

29. Contaldi C, D’Aniello C, Panico D, Zito A, Calabrò P, Di Lorenzo E et al. Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment. Life. 2025;15(3):471. DOI: 10.3390/life15030471

30. Khidirova L.D., Andreeva M.A., Roman G.N. Cardiotoxicity of chemotherapy: state of the problem and challenges of modern oncology. Creative Cardiology. 2024;18(S):64–71. DOI: 10.24022/1997-3187-2024-18S-S64-S71

31. Kogoniya L.M., Rusanov M.O., Shikina V.E. Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors. Oncohematology. 2022;17(3):127–36. DOI: 10.17650/1818-8346-2022-17-3-127-136

32. Doundoua D.P., Staferov A.V., Sorokin A.V., Kedrova A.G. Cardiooncology: chemotherapy drugs and radiation therapy impact on cardiovascular system. Clinical Practice. 2016;4(28):41–8.

33. Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. International Journal of Cardiology. 2019;280:163–75. DOI: 10.1016/j.ijcard.2019.01.038

34. Potievskaya V.I., Akhobekov A.A. Classification of cardio-oncology syndromes in assessing the interaction of cardiovascular diseases and cancer. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;16(5):529–39. DOI: 10.17116/kardio202316051529

35. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews Cardiology. 2020;17(8):474–502. DOI: 10.1038/s41569-020-0348-1

36. Potievskaya V, Khoronenko V, Kononova E, Paderina E, Fashafsha Z, Kaprin A. Case Report: Takotsubo cardiomyopathy caused by acute surgical pathology against the background of colorectal cancer. Frontiers in Cardiovascular Medicine. 2025;12:1586353. DOI: 10.3389/fcvm.2025.1586353

37. Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Shupenina E.Yu., Ballyuzek M.F., Barinova I.V. et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):152–233. DOI: 10.15829/1560-4071-2021-4703

38. Matskeplishvili S.T., Potievskaya V.I., Popovkina O.E., Bolotina L.V., Shklya eva A.V., Poluektova M.V. et al. Cardiovascular complications in the treatment of oncological diseases (cardio-oncology): prevention, diagnosis, treatment - consensus of experts. Technologies of Living Systems. 2018;15(6):3–42. DOI: 10.18127/j20700997-201806-01

39. Rakisheva A, Farmakis D, Attanasio A, Genis AB, Cohen‐Solal A, Gulati G et al. Prevention of cancer therapy‐related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio‐Oncology. European Journal of Heart Failure. 2025;ejhf.3753. [Epub ahead of print]. DOI: 10.1002/ejhf.3753

40. Vasyuk Yu.A., Vyzhigin D.A., Shupenina E.Yu., Novosel E.O., Ulyanova E.A. New opportunities for preclinical diagnostics of antitumor therapy cardiotoxicity: results of an observational study. Rational Pharmacotherapy in Cardiology. 2025;21(3):209–16. DOI: 10.20996/1819-6446-2025-3187

41. Emelina E.I., Gendlin G.E., Nikitin I.G. Cardio-oncology and Oncohematology: Examination Algorithms, Prophylactic and Treatment of Cardiotoxicity, Trends in Rehabilitation. Clinical oncohematology. 2021;14(2):239–61. DOI: 10.21320/2500-2139-2021-14-2-239-261

42. Chazova I.E., Ageev F.T., Aksenova A.V., Vicenya M.V., Gilyarov M.Yu., Martynyuk T.V. et al. Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Eurasian heart journal. 2022;1(38):6–79. 10.38109/2225-1685-2022-1-6-79

43. Vasyuk Yu.A., Muslov S.A., Vyzhigin D.A., Shupenina E.Yu., Novosel E.O. Determining The Risk of Cardio- and Vasotoxicity of Antitumor Therapy: to Whom, When, Why? Kardiologiia. 2025;65(1):3–10. DOI: 10.18087/cardio.2025.1.n2717

44. Akildzhonov F.R., Buziashvili Yu.I., Asymbekova E.U., Artamonova E.V., Tugeeva E.F. Global left ventricular strain: chemotherapy-associated cardiotoxicity. Creative Cardiology. 2022;16(1):15–25. DOI: 10.24022/1997-3187-2022-16-1-15-25

45. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 2017;35(8):893–911. DOI: 10.1200/JCO.2016.70.5400

46. Seferovic P, Coats A, Filippatos G, Bauersachs J, Rosano G. The ESC Textbook of Heart Failure. - Oxford: Oxford University Press; 2023. - 1040p. ISBN 978-0-19-889162-8

47. Teplyakov A.T., Shilov S.N., Popova A.A., Grakova E.V., Berezikova E.N., Neupokoeva M.N. et al. The cardiovascular system in patients with anthracycline cardiomiopathy. Bulletin of Siberian Medicine. 2017;16(3):127–36.

48. Gendlin G.E., Emelina E.I., Nikitin I.G., Vasyuk Yu.A. Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines. Russian Journal of Cardiology. 2017;22(3):145–54. DOI: 10.15829/1560-4071-2017-3-145-154

49. Karimov R.R., Bochkarnikova O.V., Khabarova N.V., Belenkov Yu.N., Ilgisonis I.S. Vasculotoxicity of anthracycline antibiotics: the current state of the problem. Cardiology: News, Opinions, Training. 2024;12(4):39–48. DOI: 10.33029/2309-1908-2024-12-4-39-48

50. Pershukov I.V., Akbalaeva B.A., Shulzhenko L.V., Batyraliev T.A., Gurovich O.V., Vinogradskaya V.V. et al. Echo-loop of subclinical cardiovascular toxicity in women associated with HER2-positive breast cancer therapy. Cardiovascular Therapy and Prevention. 2024;23(6):57–65. DOI: 10.15829/1728-8800-2024-4038

51. Potievskaya V.I., Akhobekov A.A., Bolotina L.V., Koroleva L.A., Kaprin A.D. Cardiovascular complications of antitumor therapy for breast cancer: diagnosis, prevention and treatment. Siberian journal of Oncology. 2021;20(5):138–48. DOI: 10.21294/1814-4861-2021-20-5-138-148

52. Subbotin A.K., Tarlovskaya E.I., Chichkanova A.S. Evaluation of cardiotoxicity of chemotherapeutic treatment in breast cancer patients according to a local register. South Russian Journal of Therapeutic Practice. 2021;2(3):48–55. DOI: 10.21886/2712-8156-2021-2-3-48-55

53. Klimkin P.F., Shalenkova M.A., Ovchinnikova E.G. Cardio toxic effects of antitumor therapy for colorectal cancer. The Doctor. 2023;34(9):55–8. DOI: 10.29296/25877305-2023-11-14

54. Ballyuzek M.F., Kuzin S.O., Khaimanova D.G., Sholokhov G.V. The Characteristics of Cardiovascular Adverse Events in Therapy with Immune Checkpoint Inhibitors: The Result of Work of the Multi-Disciplinary Team. Problems in oncology. 2024;70(3):541–9. DOI: 10.37469/0507-3758-2024-70-3-541-549

55. Buziashvili Yu.I., Asymbekova E.U., Tugeeva E.F., Artamonova E.V., Akildzhonov F.R. Cardiotoxicity of checkpoint inhibitors: focus on immune side effects. Medical alphabet. 2024;7:26–33. DOI: 10.33667/2078-5631-2024-7-26-33

56. Fashafsha Z.Z., Mesitskaya D.F., Kopylov F.Yu., Salpagarova Z.K., Bykova A.A. Diagnostic aspects of cardiovascular complications following chemotherapy. Cardiology and Cardiovascular Surgery. 2022;15(1):40–5. DOI: 10.17116/kardio20221501140

57. Buziashvili Yu.I., Stilidi I.S., Asymbekova E.U., Matskeplishvili S.T., Artamonova E.V., Akhmediarova N.K. et al. A complex approach to continuous cardiac monitoring of neoadjuvant chemotherapy: Observational study. Consilium Medicum. 2022;24(6):399–407. DOI: 10.26442/20751753.2022.6.201700

58. Kirichenko Yu.Yu., Varsieva V.G., Shestakova K.M., Chernichkina A.D., Palienko A.V., Buduscheva O.I. et al. Metabolomic Profiling as a Potential Tool for Predicting Cancer Therapy-Related Cardiovascular Toxicity: a Pilot Single-Center Study. Kardiologiia. 2025;65(6):3–11. DOI: 10.18087/cardio.2025.6.n2936

59. Kirichenko Yu.Yu., Ilgisonis I.S., Levin P.A., Belenkov Yu.N. Prognostic value of vascular remodeling parameters in the development of adverse cardiovascular events in patients with gastric cancer. Russian Journal of Cardiology. 2022;27(11):14–21. DOI: 10.15829/1560-4071-2022-5230

60. Buziashvili Yu.I., Matskeplishvili S.T., Asymbekova E.U., Tugeeva E.F., Akildzhonov F.R. Molecular and genetic aspects of cardiotoxicity of anticancer chemotherapy. Creative Cardiology. 2024;18(S):57–63. DOI: 10.24022/1997-3187-2024-18S-S57-S63

61. Plokhova E.V., Doundoua D.P. Cardiooncology. Basic principles of prevention and treatment of cardiotoxicity in cancer patients. Journal of Clinical Practice. 2019;10(1):30–40. DOI: 10.17816/clinpract10130-40

62. Vasyuk Yu.A., Novosel E.O., Shupenina E.Yu., Vyzhigin D.A., Khabarova N.V., Belenkov Yu.N. Results of a Single-Center Prospective Observational Study: How to Take Care of the Heart of a Cancer Patient. Kardiologiia. 2025;65(8):12–21. DOI: 10.18087/cardio.2025.8.n2944

63. Chazova I.E., Tyulyandin S.A., Vitsenya M.V., Ovchinnikov A.G., Poltavskaya M.G., Gilyarov M.Yu. et al. Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I. Systemic Hypertension. 2017;14(3):6–20. DOI: 10.26442/2075-082X_14.3.6-20

64. Akildzhonov F.R., Buziashvili Yu.I., Asymbekova E.U., Tugeeva E.F., Alimov V.P. Early prevention of cardiotoxicity in oncology patients: focus on pharmacotherapy. Creative Cardiology. 2021;15(3):322–31. DOI: 10.24022/1997-3187-2021-15-3-322-331

65. Gomaa NF, Werida RH, EL-Gowily AG, El-Bassiouny NA. Evaluating the role of montelukast on doxorubicin-induced cardiotoxicity in breast cancer patients. Supportive Care in Cancer. 2025;33(10):897. DOI: 10.1007/s00520-025-09947-z

66. Buziashvili Yu.I., Stilidi I.S., Matskeplishvili S.T., Asymbekova E.U., Tugeeva E.F., Artamonova E.V. et al. Cardiovascular and oncological diseases — focus on modifiable risk factors and modern pathogenetic aspects. Annals of the Russian academy of medical sciences. 2023;78(2):132–40. DOI: 10.15690/vramn8359

67. Barinova I.V., Vitsenya M.V., Ageev F.T., Pogosova N.V. Exercise in rehabilitation of patients with breast cancer. Russian Cardiology Bulletin. 2022;17(4):16–23. DOI: 10.17116/Cardiobulletin20221704116

68. Kirichenko Yu.Yu., Ilgisonis I.S., Chernichkina A.D., Palienko A.V., Buduscheva O.I., Pakhtusov N.N. et al. 4-Year Experience of the Cardio-Oncology Center of Sechenov University: Single-Center Epidemiological Study. Kardiologiia. 2024;64(10):32–9. DOI: 10.18087/cardio.2024.10.n2768

69. Fiuza M, Magalhães A, Nobre Menezes M, Costa P, Abreu Ribeiro L, Abreu C et al. Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: An observational study. Revista Portuguesa de Cardiologia. 2022;41(12):979–84. DOI: 10.1016/j.repc.2021.07.014